Arlington Partners’s GSK GSK Stock Holding History

Arlington Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-5,388	Closed	-$282K	–	27
2026 Q2	$282K	Buy	5,388 +1,006	+23%	+$53.2K	0.51%	15
2026 Q1	$242K	Buy	+4,382	New	+$237K	0.48%	21
2025 Q4	–	Sell	-125,748	Closed	-$5.43M	–	27
2025 Q3	$5.43M	Buy	125,748 +64,746	+106%	+$2.53M	1.88%	8
2025 Q2	$2.34M	Buy	+61,002	New	+$2.33M	0.86%	55
2023 Q3	–	Sell	-320	Closed	-$11.4K	–	503
2023 Q2	$11.4K	Buy	+320	New	+$11.5K	﹤0.01%	454
2022 Q1	–	Sell	-416	Closed	-$23K	–	532
2021 Q4	$23K	Buy	+416	New	+$21.6K	0.01%	354
2020 Q2	–	Sell	-98	Closed	-$5K	–	217
2020 Q1	$5K	Sell	98 -162	-62%	-$8.64K	﹤0.01%	188
2019 Q4	$15K	Hold	260	–	–	0.01%	179
2019 Q3	$14K	Hold	260	–	–	0.01%	147
2019 Q2	$13K	Hold	260	–	–	0.01%	192
2019 Q1	$14K	Hold	260	–	–	0.01%	162
2018 Q4	$12K	Buy	+260	New	+$12.8K	0.01%	166

Other funds holding GSK

Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return

Miller Howard Investments Kingston, New York $3.72B AUM 18.2% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return

Stockman Wealth Management Billings, Montana $960M AUM 19.88% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Arlington Partners's GSK Position: Q3 2026 in Review

Arlington Partners sold out of GSK (GSK) in Q3 2026, closing a stake of 5,388 shares — an estimated $282K sold.

Arlington Partners first reported a position in GSK in Q4 2018 and held it in 12 quarters. The position peaked at $5.43M in Q3 2025. 331 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Arlington Partners reported no remaining GSK position as of Q3 2026 after selling out during the quarter.
Arlington Partners sold 5,388 GSK shares in Q3 2026, an estimated $282K.
Arlington Partners first reported a position in GSK in Q4 2018 and held it in 12 quarters.
Arlington Partners's GSK position peaked at $5.43M in Q3 2025.
331 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Arlington Partners's 13F filing for Q3 2026, filed 20 Oct 2026.